Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4B 3.73B 3.42B 6.41B 436B 6.57B 44.25B 17.31B 216B 17.08B 16.71B 746B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.85B 3.54B 6.62B 450B 6.78B 45.7B 17.87B 223B 17.64B 17.26B 770B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+1.54%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.92
Extreme 5.925
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
27/4/26 Issuer sale

General Counsel

1,264,993 0.4029%
27/4/26 Issuer sale

Director

398,261 0.1268%
27/4/26 Issuer sale

Director

395,940 0.1261%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+136.38%+6.78% 4.55B
+2.61%+7.16%-0.93%+13.91% 47.88B
+1.90%+24.70%+27.25%+9.47% 40.55B
-1.60%-1.15%+388.84%+603.70% 39.09B
-0.98%+2.28%+7.02%+45.34% 36.75B
+1.47%+5.82%+5.76%+43.52% 27.96B
-0.94%+0.05% - - 16.77B
+2.44%+10.76%+30.59%+129.56% 15.94B
-1.14%+6.52%-3.80%-29.33% 13.81B
+0.18%-2.75%+3.22%+10.14% 13.55B
Average +0.41%+4.17%+66.04%+92.56% 25.68B
Weighted average by Cap. +0.60%+4.84%+74.05%+122.29%

Financials

2024 2025
Net sales 528M 464M 433M 398M 744M 50.6B 763M 5.14B 2.01B 25.04B 1.98B 1.94B 86.56B 634M 557M 520M 477M 894M 60.75B 916M 6.17B 2.41B 30.06B 2.38B 2.33B 104B
Net income -56.11M -49.3M -46.02M -42.23M -79.06M -5.37B -81.01M -546M -213M -2.66B -211M -206M -9.19B -27.11M -23.82M -22.24M -20.41M -38.2M -2.6B -39.14M -264M -103M -1.28B -102M -99.58M -4.44B
Net Debt 194M 170M 159M 146M 273M 18.55B 280M 1.88B 737M 9.18B 727M 711M 31.74B 149M 131M 122M 112M 210M 14.26B 215M 1.45B 566M 7.05B 559M 547M 24.39B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock